BAVARIAN NORDIC/S (BVNRY) & Spark Therapeutics (ONCE) Head-To-Head Review

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) and Spark Therapeutics (NASDAQ:ONCE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Volatility and Risk

BAVARIAN NORDIC/S has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Spark Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for BAVARIAN NORDIC/S and Spark Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spark Therapeutics 0 9 12 0 2.57

Spark Therapeutics has a consensus price target of $66.55, suggesting a potential upside of 72.32%. Given Spark Therapeutics’ higher possible upside, analysts clearly believe Spark Therapeutics is more favorable than BAVARIAN NORDIC/S.


This table compares BAVARIAN NORDIC/S and Spark Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BAVARIAN NORDIC/S -126.80% -19.17% -14.54%
Spark Therapeutics -127.82% -14.18% -10.45%

Valuation & Earnings

This table compares BAVARIAN NORDIC/S and Spark Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BAVARIAN NORDIC/S $208.06 million 3.26 $27.54 million $0.29 24.10
Spark Therapeutics $12.07 million 120.79 -$253.48 million ($7.63) -5.06

BAVARIAN NORDIC/S has higher revenue and earnings than Spark Therapeutics. Spark Therapeutics is trading at a lower price-to-earnings ratio than BAVARIAN NORDIC/S, indicating that it is currently the more affordable of the two stocks.


Spark Therapeutics beats BAVARIAN NORDIC/S on 6 of the 11 factors compared between the two stocks.


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.

Leave a Reply